Built on strength and resilience
To navigate an increasingly complex economic and competitive landscape, we sharpened our focus in 2024 to further enhance Octapharma's resilience and to preserve the vitality of our business.
:quality(80))
Advancing Human Life. Together.
The Octapharma Annual Report 2024 offers a detailed insight into our company, highlighting who we are and the work we do.
)
Research & Development
Small antibodies with big implications
Tiny molecules derived from the blood of camels and llamas hold the potential to transform the treatment of patients across multiple therapeutic fields and indications. Octapharma is pioneering in the field and investing in this promising and rapidly expanding area of research.
We are reimagining global health
Meeting patient needs
1 / 5
:quality(80))
Expanding access
Shaping the future of Octapharma together
therapeutic areas
countries
employees
Inside Octapharma
Creating a healthier future
How Big Data is changing the game
Octapharma has made significant strides in becoming a data-driven company, deploying AI-powered Advanced Analytics across sites to optimise production, enhance yields, and improve operational performance.
Our strategy
Continue to ensure the safe and optimal use of human proteins and expand the portfolio to deliver innovative health solutions advancing human life.
Efficiency
Prioritise IG yield improvements and optimise plasma collection / production capacities to support future growth and increase revenues per litre.
Innovation
Strengthen our commitment to haematology, immunology and critical care by enhancing and expanding our portfolio into adjacent areas and new indications.
Accessibility
Expand accessibility of our therapies to more patients around the world.
Responsibility
Reaffirm Octapharma’s family ownership, long-term vision and commitment to patients and responsible value creation.
Engagement
Remain an employer of choice.